Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
J Nucl Med. 2023 Jun;64(6):859-862. doi: 10.2967/jnumed.122.264977. Epub 2023 Jan 19.
PET/CT with the new Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(-Me)Nle-Asp-1-Nal-NH (Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokinin-2 receptor expression status. Six patients with advanced MTC underwent PET/CT with Ga-DOTA-MGS5. From the images acquired 1 and 2 h after injection, preliminary data on the biodistribution and tumor-targeting properties were evaluated in a retrospective analysis. In total, 87 lesions with increased radiotracer uptake considered malignant were detected (2 local recurrences, 8 lymph node lesions, 27 liver lesions, and 50 bone lesions). In general, radiotracer accumulation in lesions was higher at 2 h than at 1 h after injection (mean SUV, 7.2 vs. 6.0, respectively; mean SUV, 4.4 vs. 3.6, respectively). The preliminary results clearly demonstrate the potential of Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.
使用新型 Ga 标记的 minigastrin 类似物 DOTA-dGlu-Ala-Tyr-Gly-Trp-(-Me)Nle-Asp-1-Nal-NH (Ga-DOTA-MGS5)对晚期甲状腺髓样癌 (MTC) 患者进行了 PET/CT 检查，以评估胆囊收缩素-2 受体表达状态。6 名晚期 MTC 患者接受了 Ga-DOTA-MGS5 的 PET/CT 检查。通过对注射后 1 小时和 2 小时获得的图像进行回顾性分析，评估了生物分布和肿瘤靶向特性的初步数据。共发现 87 处放射性示踪剂摄取增加的病变，认为是恶性病变（2 处局部复发、8 处淋巴结病变、27 处肝脏病变和 50 处骨病变）。一般来说，注射后 2 小时比 1 小时时病变内的放射性示踪剂积聚更高（平均 SUV 分别为 7.2 和 6.0，平均 SUV 分别为 4.4 和 3.6）。初步结果清楚地表明了 Ga-DOTA-MGS5 PET/CT 在检测晚期 MTC 患者局部复发和转移方面的潜力。
